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Abstract 
Peripheral T-cell lymphoma comprises a heterogeneous group of mature non-Hodgkin 
lymphomas. Their diagnosis is challenging, with up to 30% of cases remaining unclassifiable 
and referred to as “not otherwise specified”. We developed a reverse transcriptase-
multiplex ligation-dependent probe amplification gene expression profiling assay to 
differentiate the main T-cell lymphoma entities and to study the heterogeneity of the “not 
specified” category. 
The test evaluates the expression of 20 genes, including 17 markers relevant to T-cell 
immunology and lymphoma biopathology, one EBV-related transcript, and variants of RHOA 
(G17V) and IDH2 (R172K/T). 
By unsupervised hierarchical clustering, our assay accurately identified 21/21 ALK-positive 
anaplastic large cell lymphomas, 16/16 extranodal NK/T-cell lymphomas, 6/6 hepatosplenic 
T-cell lymphomas, and 13/13 adult T-cell leukemia/lymphomas. ALK-negative anaplastic 
lymphomas (n=34) segregated into one cytotoxic cluster (n=10) and one non-cytotoxic 
cluster expressing Th2 markers (n=24) and enriched in DUSP22-rearranged cases. The 63 
T
FH
-derived lymphomas divided in two subgroups according to a predominant T
FH
 (n=50) or 
an enrichment in Th2 (n=13) signatures.  We next developed a support vector machine 
predictor which attributed a molecular class to 27/77 not specified T-cell lymphomas: 17 
T
FH
, 5 cytotoxic ALK-negative anaplastic, and 5 NK/T-cell lymphomas. Among the remaining 
cases, we identified two cell-of-origin subgroups corresponding to cytotoxic/Th1 (n=19) and 
Th2 (n=24) signatures. A reproducibility test on 40 cases yielded a 90% concordance 
between 3 independent laboratories. 
This study demonstrates the applicability of a simple gene expression assay for the 
classification of peripheral T-cell lymphomas. Its applicability to routinely-fixed samples 
makes it an attractive adjunct in diagnostic practice. 
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Introduction 
Peripheral T-cell lymphomas (PTCLs) are a diverse group of neoplasms, representing 
10-15% of all lymphomas worldwide, with large geographic variation. According to the 2017 
revision of the World Health Organization (WHO) classification of lymphoid neoplasms, 
PTCLs comprise up to 30 entities derived from various subsets of mature T or NK cells (1). 
The heterogeneity and rarity of these tumors, combined with their complex 
immunophenotypic profile and partially overlapping features across different entities, make 
their diagnosis particularly challenging. In addition, there is a high variability in the 
diagnostic workup among pathologists, which may account for relatively poor 
reproducibility of the diagnoses (2–4). Although most cases can be ascribed to specific 
disease entities, approximately one third of PTCLs not fulfilling the criteria for other entities 
remain unclassifiable and are categorized “by default” as PTCL-NOS. 
The classification of PTCLs has undergone major changes over the past years, due to the 
incorporation of many new information on their genetic background and taking into account 
the notion that PTCL arise from discrete subsets of normal T cells. In recent years, the 
description of the signature and mutational landscape of PTCLs has generated novel 
molecular biomarkers to refine the diagnostic criteria for some entities. Notably, the 
expression of T
FH
 markers and the presence of genetic lesions associated with angio-
immunoblastic T-cell lymphoma (AITL) (such as RHOA, TET2, DNMT3A, and IDH2 mutations), 
found in a significant proportion of PTCL-NOS (5–10), led to the reclassification of these as 
“nodal PTCL with a T
FH
 phenotype” (T
FH
-PTCL) in the revised WHO classification (1). Among 
anaplastic large cell lymphoma (ALCL), the identification of recurrent rearrangements of the 
ALK gene led to individualize ALK-positive ALCL as a definitive entity (ALCL ALK+), and to 
reconsider ALCL without ALK rearrangement as a distinct but genetically heterogeneous 
group comprising subtypes characterized by alterations of the DUSP22/IRF4 or TP63 genes 
with distinct clinical, pathological and biological features (11). Among the remaining PTCL-
NOS category, two molecular subgroups defined by the expression of the TBX21 and GATA3 
transcription factors have been proposed (12,13), with a worse prognosis suggested for 
GATA3-positive cases (13–16). In daily diagnostic practice, however, high-throughput 
technologies are difficult to integrate. Moreover, the immunohistochemical surrogates are 
not fully validated and require an increasingly large panel of antibodies, and their evaluation 
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may present some difficulties or limitations (3,17). 
Here, we designed a simple targeted mRNA expression profiling assay based on reverse 
transcriptase-multiplex ligation-dependent probe amplification (RT-MLPA), using a panel of 
molecular markers relevant to the characterization of PTCL. We first assessed the accuracy 
of this assay in the classification of PTCL entities other than PTCL-NOS, and then used the 
assay to study the heterogeneity of PTCL-NOS. Our findings support this RT-MLPA assay as a 
robust and useful tool, suitable for the routine classification of PTCLs and therefore an 
optimal clinical management of PTCL patients. 
 
Methods 
Patients and tumor samples 
A series of 270 lymphoma samples were selected within the framework of the multicentric 
T-cell lymphoma consortium (TENOMIC), of the Lymphoma Study Association (LYSA). All 
cases had been reviewed by at least two expert hematopathologists, according to the 
criteria of the recently updated WHO classification (1). The series was enriched in nodal T
FH
-
PTCL (T
FH
-PTCL) defined by the expression of at least 2 T
FH
 markers among CD10, BCL6, 
CXCL13, PD1, ICOS and in PTCL-NOS defined as a diagnosis of exclusion of any well-defined 
entity. The design of the study is summarized in Figure 1. Briefly a classification cohort 
(n=230) was used to train a SVM classifier and a diagnostic cohort (n=40) was used to 
evaluate its inter-laboratory reproducibility on FFPE samples. The study was approved by 
the local ethics committee (CPP Ile de France IX 08-009). 
 
RT-MLPA assay gene expression profiling 
RNA extracted from frozen and/or FFPE tumor samples was applied to RT-MLPA (for details, 
see reference 18 and Supplemental Methods). Briefly, this targeted multiplex assay consists 
of the hybridization and ligation of specific probes on cDNA, followed by PCR amplification. 
We designed 41 probes (Eurofins MWG Operon, Ebersberg, Germany) targeting 20 genes, 
selected for their relevance to PTCL classification (Table 1). RTMLPA results were compared 
to Affymetrix HG-U133-plus-2.0 gene expression data in 72 previously reported 
cases(18,19). 
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Bioinformatic analysis 
A web interface was developed for the complete analysis of the RT-MLPA results 
(https://bioinfo.calym.org/RTMLPA). A support vector machine (SVM) was developed to 
classify PTCL samples: two-thirds of the 184 PTCLs of the classification cohort which 
clustered in defined molecular branches according to the clustering (Figure 4), were 
randomly selected to train the classifier, which was validated in the remaining third cases. A 
bootstrap resampling process was used to build 100 independent training and validation 
series. A definitive SVM predictor was thus trained using the 184 cases. This supervised 
learning model assigns a class to every PTCL sample. Therefore, we integrated the distance 
to the centroid of the predicted class for each sample to avoid classifying distant samples 
into the same group. The analytical process is detailed in Supplemental Methods. 
Histopathology and molecular validation 
RT-MLPA signatures were correlated to immunochemical data, including expression of 
GATA3 and TBX21. The cut off for positive immunohistochemical staining was 10% of 
presumed neoplastic cells (detailed in supplemental methods). FISH for DUSP22/IRF4 
rearrangement was performed in 20 ALCLs. Mutations were validated using PCR allele-
specific and/or targeted deep sequencing (20,21). Technical details are presented in 
Supplemental Methods. 
 
Data analysis 
Affymetrix and RT-MLPA gene expression values were correlated using Spearman’s 
correlation test. Correlations between immunohistochemical results and RT-MLPA gene 
expression values were evaluated using Wilcoxon’s rank-sum test. Unsupervised hierarchical 
analysis was performed using the Ward method. 
Overall and progression free survival analysis were performed using Kaplan Meier method 
and the log-rank test. The Mann-Whitney test was used to analyze continuous data and the 
Fisher exact test to analyze categorical data. 
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Results 
Design and validation of the RT-MLPA assay 
The design of the study is presented in Figure S1. The gene set and sequences of the RT-
MLPA probes are shown in Tables 1 and Table S1, respectively. The panel was designed to 
include several genes encoding immunohistochemical or genetic markers routinely used for 
the diagnosis of PTCL and genes of interest selected from previous transcriptomic and 
genomic studies(9,10,12,13,18). It includes genes related to the major CD4 and CD8 T-cell 
subsets, genes defining the main subsets of Th cells [T
FH
 (CXCL13, CXCR5, ICOS, BCL6), Th1 
(TBX21, IFNT), Th2 (GATA3, CCR4), and Treg (FOXP3)], as well as genes encoding cytotoxic 
molecules (PRF, GZMB). CD30 and ALK were chosen to identify ALCL and CD56 and EBER1 
(Epstein-Barr virus encoding small RNAs) were selected to identify HSTL and NKTCL. We also 
included the RHOAG17V and IDH2R172K/T variants, as the most prevalent hotspot 
mutations of T
FH
-derived PTCL. 
We obtained RT-MLPA profiles for all 230 PTCLs of the classification cohort. Representative 
RT-MLPA profiles for each entity are shown in Figure S2. T
FH-
PTCL profiles were 
characterized by the expression of a combination of T
FH
 genes (CXCL13, CXCR5, ICOS, and 
BCL6), together with frequent RHOA and/or IDH2 variants. ATLLs expressed Th2 markers 
(GATA3 and CCR4) and ICOS, with variable levels of FOXP3. NKTCL showed high expression 
of EBER1 and GZMB, as well as Th1 markers (TBX21 and IFNγ). HSTL expressed CD56, GATA3, 
TBX21, and BCL6. ALK-positive ALCL expressed ALK, CD30, PRF, and GZMB. ALK-negative 
ALCLs comprised two distinct profiles, with or without expression of PRF and GZMB. The 
non-cytotoxic ALCLs showed high expression of CD30 and Th2 markers (GATA3 and CCR4) 
but not PRF or GZMB. Unexpectedly, RT-MLPA identified ALK expression in a case of ALCL 
initially considered ALK-negative (based on negative immunostaining with the ALK1 clone), 
leading to reclassification to ALK-positive ALCL. This was further confirmed by IHC using an 
alternative antibody (D5F3 clone) (Figure S3). 
Paired RT-MLPA profiles and Affymetrix gene expression data available in 72 cases 
(23 AITL and 49 PTCL-NOS) were compared(18,19). There were significant correlations for 
each evaluable gene (TNFRSF8/CD30, PRF, GZMB, GATA3, CXCL13, ICOS, CD8, BCL6, CD4, 
FOXP3, CCR4, CXCR5, and TBX21) (Figure S4). RT-MLPA and immunohistochemical data 
scores also showed significant correlations for the 12 evaluable markers (Figure S5). There 
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was also a good correlation with the EBER in situ hybridization results, showing the capacity 
of the assay to correctly detect EBV infection. RT-MLPA profiles performed in duplicates in 
20 PTCLs on RNAs extracted from both frozen and FFPE samples, showed a strong 
correlation (rho>0.7, Spearman correlation test, Figure S6). 
RT-MLPA identified 33/33 RHOAG17V and 9/10 IDH2 R172K/T mutations, detected 
by either AS-qPCR and/or NGS studies. The only RT-MLPA failure corresponded to an AITL 
with an IDH2R172K mutant with a 2.8% allele frequency, which was only detected by NGS 
(see details in Table S2). 
Unsupervised analysis highlights heterogeneity among ALK-negative ALCL and TFH-PTCL  
Given the expected heterogeneity of PTCL-NOS, we first restricted our analyses to specified 
PTCL entities (not taking into account PTCL-NOS). Unsupervised hierarchical clustering 
performed on 153 such cases (30 AITLs, 33 T
FH
-PTCL, 16 NKTCLs, 13 ATLLs, 6 HSTLs, 21 ALK-
positive ALCLs and 34 ALK-negative ALCLs) identified 2 main branches separating cytotoxic 
and non-cytotoxic entities, as shown in Figure 1.  
The cytotoxic branch is divided into 2 clusters, one very homogeneous cluster (C5) 
comprising the 16 NKTCLs, and a second cluster (C6) composed of 31 cytotoxic ALCLs (21 
ALK-positive and 10 ALK-negative). The other branch is divided into four clusters (C1-4). The 
C1 cluster contained the 6 HSTL. The 63 PTCLs with a T
FH
 phenotype (AITL and T
FH
-PTCL) 
distributed along the two clusters C2 and C3. The C2 cluster comprised a major group of 
AITL/T
FH
-PTCL characterized by a T
FH
 signature (C2, n=50). In addition to 12 ATLLs, 13 T
FH
-
PTCL and one AITL in the C3 cluster showed an enrichment in T
FH
 and Th2 markers. 
Interestingly, RHOA mutations were identified in 26/50 (52%) and 2/13 (15%) of the C2 and 
C3 clusters respectively (p=0.027). By immunohistochemistry, these T
FH
-PTCL in the C3 
cluster showed expression of GATA3 (in more than 50% of tumor cells) in 9/12 (75%) 
contributive cases (Figure 2). The C4 cluster contained 24 ALK-negative non-cytotoxic ALCLs 
with Th2 signature, with 8/16 contributive cases showing DUSP22 rearrangement by FISH. 
 
PTCL-NOS distribute among distinct clusters using unsupervised clustering 
When applied to all 230 PTCL samples (including 77 PTCL-NOS), unsupervised clustering 
showed that the majority of PTCL-NOS (n = 48/77, 62.3%) clustered within four of the six 
previous clusters as they showed gene signatures in common with molecular T
FH-
PTCL (C2, n 
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= 6), T
FH
/Th2 PTCLs (C3, n = 19), NKTCL (C5, n = 5), and cytotoxic ALCL (C6, n = 18) (Figure 3). 
Despite a variable expression of CD30 by immunohistochemistry, 18 PTCL-NOS distributed 
within the cluster of cytotoxic ALCL based on the expression of cytotoxic markers plus TBX21 
and IFN , consistent with a possible Th1 origin. Accordingly, 8/12 of these cases tested for 
TBX21 by immunohistochemistry were positive. This molecular subgroup is further referred 
as “cytotoxic/Th1 PTCL” according to its signature. In addition, 19 other PTCL-NOS cases, all 
with negative HTLV-1 serologies, clustered with ATLL, based on an enrichment in Th2 
molecules GATA3 and CCR4 and are referred to as molecular “Th2 PTCL”. Finally, 29 PTCL-
NOS did not cluster within any of the defined branches, and segregated with 19 other cases 
(4 AITLs, 12 T
FH
-PTCL, 1 ATLL). 
A SVM classifier accurately classifies specified PTCLs and identifies subgroups within PTCL-
NOS 
We next built a support vector machine (SVM) model to assign each case to a class based on 
the RT-MLPA data (Figure 4A). One hundred and eighty-four PTCLs corresponding to the 
molecular groups defined according to the latter clustering (Figure 3) were used for the 
construction of the model and to define the molecular classes: 45 T
FH
-PTCL/AITLs, 21 
NKTCLs, 42 Th2 PTCL-NOS/ATLL, 50 cytotoxic-ALCLs, 20 non-cytotoxic ALCLs, and the 6 
HSTLs. The 46 PTCLs which did not cluster within these 6 defined branches were not 
considered to train the classifier. The SVM algorithm accurately assigned 140/153 specified 
PTCLs to the correct categories: 16/16 NKTCL, 13/13 ATLL, 6/6 HSTL, 31/31 cytotoxic ALCL, 
24/24 non-cytotoxic ALK-negative ALCL cases and 50/63 AITL/T
FH
-PTCL. To note, 11 T
FH
-PTCL 
without RHOA mutation were classified as molecular Th2 PTCL, 1 as molecular cytotoxic/Th1 
and one AITL was distant from the barycenter of the T
FH
/AITL class and not classified. Of the 
77 remaining PTCL-NOS, 70 (91%) were classified by the SVM as T
FH
/AITL (C2, n=17), 
cytotoxic/Th1 PTCL (C6, n=19), ALK-negative ALCL (C6, n=5), NKTCL (C5, n=5) while 24 cases 
were molecularly designated Th2 PTCL (C3).  Finally, 7 cases, which were distant to the 
barycenter of their predicted SVM class (2 Th2, 3 T
FH
/AITL, 2 cytotoxic/Th1) could not be 
attributed a molecular class by the SVM. Figure 4B illustrates the subgroups of PTCL-NOS as 
evidenced in the principal component analysis (PCA). A correlation of the SVM class with the 
histopathological data of the 77 PTCL-NOS is presented in Figure S7. 
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Clinico-pathological correlations of the SVM classes 
Survival data were available for 88.7% (204/230) of the patients. The median duration of 
follow-up was 122 months (interquartile range IQR = 80.5-173). Among the 132/175 
patients with follow-up data available who received anthracyclin-based chemotherapy, the 
median overall survival (OS) and progression free survival (PFS) were 15 months (IQR = 6-
51.5) and nine months (IQR = 3-36), respectively. The outcome of PTCL patients was poor 
(5y OS = 27%), except for those with ALK-positive ALCL (5y OS = 70%) as shown in Figure 6A.  
Considering the two clusters observed among PTCL with a T
FH
 phenotype (Figure 1), we 
failed to demonstrate any significant clinical difference (see Table 3). Interestingly, 
RHOAG17V mutations were found in 52% and 15.4% respectively among the C2 (T
FH
) and C3 
(Th2) clusters (p=0.02). TET2 mutations were observed in 60.6% and 14.3% of the C2 and C3 
clusters (p=0.039). DNMT3A and IDH2 mutations were found respectively in 25% and 20% of 
the C2 cluster but none within the C3 (p=ns). 
Among ALCL, non-cytotoxic ALK-negative ALCLs were characterized by the expression of Th2 
mRNAs (GATA3 and CCR4) and GATA3 expression by immunohistochemistry in 11/12 
informative cases. As shown in figure 5A, non-cytotoxic and cytotoxic ALK-negative ALCL 
disclosed similar PFS and OS. However, despite similar main clinical characteristics (Table 
S4), patients with a DUSP22-rearrangement (n=8) tended to have a favorable outcome (5y 
OS = 62.5%) close to that of ALK-positive ALCL patients (70% five-year OS), compared to the 
very poor prognosis of patients without DUSP22 rearrangement (n=8) (5y OS = 12.5%, 
p=0.07) (Figure 5B). No TP63 rearrangement was detected in this series. 
Finally, within the sized limit of the current series, among PTCL-NOS, there was no 
significant difference in patient’s outcome of with respect to their “Th1/cytotoxic” or “Th2” 
molecular signatures (Figure 5C), or immunohistochemical profiles (Figure 5D).  
 
Reproducibility of the RT-MLPA assay among three centers in routine practice 
We evaluated the reproducibility of the RT-MLPA assay in the diagnostic setting by testing 
40 FFPE PTCL samples in three independent centers. A concordance in the diagnostic class 
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proposed by the classifier was observed between the three centers for 36 (90%) samples 
(Table 2), with a strong correlation between the RT-MLPA values for each gene (Table S3). 
Among the 36 concordant samples, the SVM class was in accordance with the pathological 
diagnosis for 32 cases (89%). The four discrepancies consisted of two tumor-cell rich AITL 
assigned to the Th2/ATLL-like group, as previously observed in the classification cohort, one 
AITL with a prominent cytotoxic T cell environment assigned to the cytotoxic/Th1-like group, 
and one ATLL with a double CD4/CD8 phenotype that was not classified.  
 
Discussion 
The classification of PTCLs is often challenging and poorly reproducible, with a recent study  
showing a 31.5% rate of discrepancy between the referral and expert diagnoses (4), likely 
due to the complexity of these rare neoplasms and the wide range of practices among 
pathologists and laboratories (3). Hsi et al. pointed the limited number of 
immunohistochemical markers assessed in the routine practice, especially the T
FH
 markers, 
resulting in a poor characterization of PTCLs and a high frequency of PTCL-NOS diagnosed in 
the US (22). The ligation-dependent RT-PCR assay has been reported to be a simple and 
robust assay applicable to FFPE samples, that can be used to classify DLBCL into GCB or ABC 
subtypes (23,24). Here, we expanded that RT-MLPA can contribute in the routine setting to 
classify the main specified categories of non-cutaneous PTCL. This assay, which can be 
performed in a limited time (48 hours), requires only commonly used equipment, including 
a thermocycler and genetic fragment size analyzer. The profiles are publicly accessible and 
easy to interpret through a dedicated website. Finally, the assay is cost-effective 
(approximately five dollars per sample) (23). RT-MLPA is a useful tool in combination with 
pathological evaluation to characterize PTCLs, especially when immunohistochemistry is 
flawed or incomplete. In addition to evaluate the expression of Th-differentiation antigens 
and markers suitable for immunohistochemistry, the current RT-MLPA assay also provides 
genetic information, such as RHOA and IDH2 mutations, which are highly relevant for the 
diagnosis of PTCL of T
FH
 origin (19), even though the RHOA G17V mutation has also been 
reported in a small minority of ATLL (25), as observed in one case of our series. The accurate 
classification of specified PTCLs other than NOS entities in most cases corroborates the 
relevance of the designed gene panel. Altogether, though some markers in our RT-MLPA 
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assay might not be useful in every PTCL case, this “one fits all” assay evaluates diagnostic 
markers covering the different PTCL entities in a systematic and cost-effectiveness way. 
In addition, the RT-MLPA assay highlighted the heterogeneity in the gene signature of ALK-
negative ALCL and PTCL of T
FH
 origin as defined in the updated WHO classification. We 
observed that a significant proportion of ALK-negative ALCLs display a distinct signature, 
with expression of CD30 and Th2 genes, but no cytotoxic markers. These cases showed a 
dense and cohesive pattern of CD30-positive anaplastic large cells but, in contrast to 
common ALCL, only few hallmark cells, absence of EMA and a frequently preserved T-cell 
programme with most T-cell antigens being retained. Genetically, this group appeared 
heterogeneous but was enriched in cases DUSP22/IRF4 rearrangement (in 8/16 non-
cytotoxic cases, versus in only 1/10 cytotoxic ALK-negative ALCLs p=0.09). Despite absence 
of significant morphological or immunophenotypic difference between cases with or 
without DUSP22 rearrangement,  we further expand here that the DUSP22 status is of 
clinical relevance with a better survival of DUSP22-rearranged ALCL (11,26). In the absence 
of TP63 rearrangement (data not shown), further investigations are needed to explore the 
genetic abnormalities in the DUSP22-non rearranged cases. 
Within the umbrella category of nodal PTCL of T
FH
 derivation, comprising AITL and a number 
of nodal PTCL previously classified under PTCL-NOS but expressing 2 or more T
FH
 markers, 
our study interrogates the biological and clinical significance of two subgroups (1). Indeed, 
whereas the majority (79%) was attributed to the T
FH
/AITL class by the molecular classifier, a 
minority disclosed, in addition to T
FH
 markers, enrichment in Th2 genes. We confirmed a 
“mixed” T
FH
/Th2 immunophenotype for nine T
FH
-PTCLs showing a Th2 signature by RT-
MLPA. It has been reported that Th1 and Th2 cells can express T
FH
 markers, and conversely 
that T
FH
 cells have the capacity to express Th1 or Th2 cytokines (23,24). It has also been 
suggested that a subset of TFH cells may originate from Th2 lymphocytes in the presence of 
B cells and that T
FH
 cells can acquire GATA3 expression (25,26). Overall, these data raise the 
question of Th cell plasticity and the specificity of the criteria required to assess T
FH
-derived 
PTCLs. Indeed, the current definition of a T
FH
 phenotype based on two or more T
FH
 markers 
may have some limitations in certain cases (1) and the integration of genetic markers, made 
possible by the RT-MLPA assay, may be helpful. In this respect, when comparing the 
“TFH/AITL” class to the other SVM classes, it appeared that, among the four TFH genes in 
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our RT-MLPA panel (BCL6, CXCL13, CXCR5, ICOS), ICOS and then BCL6 appeared less specific 
than CXCL13 and CXCR5 (data not shown). Further studies however are needed to 
determine whether cases with a “mixed” T
FH
-Th2 RNA profile or immunophenotype are 
better considered as T
FH
-PTCL or Th2 PTCL-NOS with associated T
FH
 markers. The quasi-
absence of RHOA and TET2 mutation in the cases with a Th2-like profile may support the 
latter hypothesis. 
Our targeted RT-MLPA panel confirmed two subgroups among PTCL-NOS, based on the 
expression of TBX21 and cytotoxic markers or GATA3 and CCR4 in 39% and 31% of cases, 
respectively, expanding previous studies (13,14). The prognostic relevance of these 2 groups 
is controversial (27). Within the limits of our retrospective study, we failed to demonstrate 
any significant correlation with outcome between the Th1 and Th2 molecular or phenotypic 
subgroups. Additionally, all TBX21 cases in our series had a cytotoxic profile by RT-MLPA and 
immunohistochemistry. Among PTCL-NOS with a cytotoxic phenotype, the RT-MLPA assay 
highlighted a small group of cases with an EBV signature, now referred to as “nodal T/NK 
lymphoma EBV-positive” according to the revised WHO classification(1). Whether these 
cases, confirmed to be EBV-positive in almost all neoplastic cells by EBER ISH, are related to 
extranodal NK/T lymphoma nasal-type warrants further investigation. Of note, the Th2 
signature based on the expression of GATA3 and CCR4 in our panel was characteristic, 
although not specific, of ATLL. The expression of GATA3 and CCR4 together with variable 
expression of FOXP3 in ATLL is in accordance with a recent study showing that the HBZ 
transcript induces CCR4 expression in CD4 T cells by enhancing GATA3 expression, whereas 
FOXP3 expression was inconsistent in ATLL. However, the distinction between PTCL-NOS 
with a Th2-like signature and ATLL requires an investigation for HTLV1 serology and/or viral 
integration (28,29). 
Finally, our SVM model proposed a class for most cases, with few discrepancies. It may be a 
useful tool in combination with the pathological evaluation, especially when 
immunohistochemistry is not conclusive or not available. In this series, 23% of cases 
diagnosed by default as PTCL-NOS due to incomplete or failure in immunohistochemistry 
were classified as T
FH
/AITL by our assay.  Unclassified or misclassified cases by RT-MLPA 
were limited to T
FH
-PTCL or AITL rich in reactive CD8-positive cytotoxic cells known to be 
abundant in a proportion of AITL (30), or cytotoxic PTCL with various reactive T
FH
 cells. These 
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cases illustrate the contribution of the microenvironment to the molecular signature, 
especially when tumor cell content is low or heterogeneous, a common problem 
encountered in all gene-expression methods. Therefore, RT-MLPA results should be 
interpreted in the light of clinical context, as well as biological and histopathological 
findings. It is to note that our assay does not represent the final answer for PTCL 
classification, but rather a step requiring an extensive reworking. 
Overall, this study demonstrates the applicability of a robust and dedicated RT-MLPA assay 
which is easily transposable to the diagnostic workflow. Its simplicity of use, applicability to 
FFPE and frozen samples, integration of genetic features, and cost-effectiveness make it an 
attractive alternative to high-throughput technologies in the routine practice. 
Implementation of RT-MLPA in further large studies, especially in the setting of clinical trials, 
may confirm how this adjunct tool can contribute to a better classification of PTCLs and 
therefore improve the management of these patients in the era of personalized medicine. 
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Table 1. Gene panel designed for the RT-MLPA assay. 
Family genes and other targets Genes 
Detection method in the routine 
practice 
Main T-cell subsets CD4 Immunohistochemistry 
CD8 Immunohistochemistry 
TCRα Not applicable 
T
FH
 CXCL13 Immunohistochemistry 
CXCR5 Not applicable 
BCL6 Immunohistochemistry 
ICOS Immunohistochemistry 
Th1 TBX21 Immunohistochemistry 
IFNγ Not applicable 
Th2 GATA3 Immunohistochemistry 
CCR4 Not applicable 
Treg FOXP3 Immunohistochemistry 
NK-associated and cytotoxic CD56 Immunohistochemistry 
PRF Immunohistochemistry 
GZB Immunohistochemistry 
Activation CD30 Immunohistochemistry 
Virus EBER In situ hybridization 
Mutations RHOAm G17V 
AS-PCR*, other sequencing 
methods 
IDH2m R172K/T 
AS-PCR*, other sequencing 
methods, immunohistochemistry 
Other ALK Immunohistochemistry, FISH 
 
*AS-PCR= allele-specific PCR 
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Table 2. Reproducibility of the RT-MLPA assay among 3 laboratories (Center 1, Center 2 and 
Center3), evaluated on 40 FFPE samples (6 ALK-positive anaplastic large cell lymphomas = ALCL 
ALK+, 4 ALCL ALK-, 13 angioimmunoblastic T-cell lymphomas = AITL, 9 NK/T cell lymphomas = 
NKTCL, 6 adult T cell lymphomas = ATLL, and 2 peripheral T-cell lymphomas not otherwise 
specified = PTCL-NOS). 
 
Pathology RT-MLPA Classification RHOAG17V/ 
IDH2 R172 
status by 
RTMLPA 
(m=mutated, 
wt= wild-type) 
Mutations detected by 
targeted next 
generation sequencing 
(NGS) 
Center1 Center2 Center3 
Concordant samples 
Case1 AITL AITL AITL AITL m/wt ND 
Case2 AITL AITL AITL AITL m/wt 
RHOA, IDH2 (R712S), TET2, 
Case3 AITL AITL AITL AITL wt/wt ND 
Case4 AITL AITL AITL AITL m/wt 
RHOA, IDH2 (R712S), TET2, 
Case5 AITL AITL AITL AITL wt/wt ND 
Case6 AITL AITL* AITL* AITL* m/wt RHOA, IDH2 (R712T), TET2 
Case7 AITL AITL* AITL* AITL* wt/wt ND 
Case8 AITL † TH2 TH2 TH2 wt/wt IDH2(R172S), TET2, CD28 
Case9 AITL† TH2 TH2 TH2 wt/wt TET2, FYN 
Case10 AITL  Cytotoxic/Th1 Cytotoxic/Th1 Cytotoxic/Th1 m/wt RHOA, TET2 
Case11 AITL  Cytotoxic/Th1 Cytotoxic/Th1 AITL m/wt ND 
Case12 AITL  AITL* TH2 AITL m/wt ND 
Case13 AITL Cytotoxic/Th1* Cytotoxic/Th1 Cytotoxic/Th1 wt/wt ND 
Case14 ALCL ALK- ALCL ALK- ALCL ALK- ALCL ALK- wt/wt ND 
Case15 ALCL ALK- ALCL ALK- ALCL ALK- ALCL ALK- wt/wt ND 
Case16 ALCL ALK- ALCL ALK- ALCL ALK- ALCL ALK- wt/wt ND 
Case17 ALCL ALK- CD30TH2* CD30TH2* CD30TH2* wt/wt TET2, TP53 
Case18 ALCL ALK+ ALCL ALK+ ALCL ALK+ ALCL ALK+ wt/wt ND 
Case19 ALCL ALK+ ALCL ALK+ ALCL ALK+ ALCL ALK+ wt/wt ND 
Case20 ALCL ALK+ ALCL ALK+ ALCL ALK+ ALCL ALK+ wt/wt ND 
Case21 ALCL ALK+ ALCL ALK+ ALCL ALK+ ALCL ALK+ wt/wt ND 
Case22 ALCL ALK+ ALCL ALK+ ALCL ALK+ ALCL ALK+ wt/wt ND 
Case23 ALCL ALK+ ALCL ALK+ ALCL ALK+ ALCL ALK+ wt/wt ND 
Case24 ATLL TH2 TH2 TH2 wt/wt ND 
Case25 ATLL TH2 TH2 TH2 wt/wt ND 
Case26 ATLL TH2 TH2 TH2 wt/wt ND 
Case27 ATLL TH2 TH2 TH2 wt/wt ND 
Case28 ATLL unclassified unclassified unclassified wt/wt ND 
Case29 ATLL  Failure Failure TH2 wt/wt ND 
Case30 NKTCL NKTCL NKTCL NKTCL wt/wt ND 
Case31 NKTCL NKTCL NKTCL NKTCL wt/wt ND 
Case32 NKTCL NKTCL NKTCL NKTCL wt/wt ND 
Case33 NKTCL NKTCL NKTCL NKTCL wt/wt ND 
Case34 NKTCL NKTCL NKTCL NKTCL wt/wt ND 
Case35 NKTCL NKTCL NKTCL NKTCL wt/wt ND 
Case36 NKTCL NKTCL NKTCL NKTCL wt/wt ND 
Case37 NKTCL NKTCL NKTCL NKTCL wt/wt ND 
Case38 NKTCL NKTCL NKTCL NKTCL wt/wt ND 
Case39 PTCL-NOS Cytotoxic/Th1 Cytotoxic/Th1 Cytotoxic/Th1 wt/wt ND 
Case40 PTCL-NOS (EBV+) NKTCL NKTCL NKTCL wt/wt ND 
† AITL tumor cell rich * distant of the samples of the predicted SVM class Among the 4 discrepant samples, 
the SVM resulted in concordance between two centers for two cases, one case showed discordant result 
between the three centers, and one ATLL sample had no interpretable profile in two centers whereas the 
other determined a Th2 profile concordant with the diagnosis 
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Table 3. Clinical, Pathological and Molecular features of the two subgroups of T
FH
-PTCL 
 
TFH signature 
n=50 
TFH and TH2 
signatures 
n=13 
p 
Clinical data 
Age median (range) 64.4 (54-74.6) 67.4 (56.7-74.7) 0.79 
IPI>=3 71.8% (28/39) 75% (9/12) 1 
PIT>=2 71% (27/38) 63.6% (7/11) 0.72 
Extranodal site>=2 50% (22/44) 58.3% (7/12) 0.75 
Stade>=3 100% (44/44) 91.7% (11/12) 0.21 
PS>=2 40% (16/40) 8.3% (1/12) 0.076 
LDH>1N 64% (25/39) 50% (6/12) 0.5 
B signs 70.7% (29/41) 45.5% (5/11) 0.16 
Hypergammaglobulinemia 37.5% (12/32) 12.5% (1/8) 0.24 
Coombs 46% (12/26) 0% (0/2) 0.49 
Anemia 61.5% (24/39) 41.6% (5/12) 0.32 
Cutaneous rash 23.8% (10/42) 33% (4/12) 0.48 
BM 48.8% (21/43) 33.3% (4/12) 0.51 
Complete response 50% (20/40) 41.7% (5/12) 0.75 
OS median (range) 22 (5.5-77) 30.5 (6-50.5) 0.91 
PFS median (range) 10 (3-39) 12 (5.5-38) 0.42 
Pathological data 
Clear cells 65.2% (30/46) 36% (4/11) 0.1 
B Blasts 90% (44/49) 66% (8/12) 0.07 
EBV positivity 70.2% (33/47) 58.3% (7/12) 0.5 
EBV extent >5 large blast-
cells/high power field 
29.5% (13/44) 0% (0/12) 0.049 
Molecular data 
TET2 mutation 60.6%% (20/33) 14.3% (1/7) 0.039 
DNMT3a mutation 25% (8/32) 0% (0/6) 0.31 
RHOA mutation 52% (26/50) 15.4% (2/13) 0.027 
IDH2 mutation 20% (10/50) 0% (0/13) 0.1 
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Figure Legends 
Figure 1. Unsupervised hierarchical clustering of PTCL entities other than PTCL-NOS using RT-MLPA 
(n = 153). The assay was used to classify AITL (n = 30), PTCL-TFH (n=33), ALCL (n = 55), ATLL (n = 13), 
HSTL (n = 6), and NKTCL (n = 16). Differential gene expression is depicted according to a red 
(positive) to blue (negative) color scale, and concordance with histopathological diagnosis 
(Pathology). Two main branches were observed: the left branch divided in 6 HTSL (C1), 50 T
FH
-
PTCL/AITL (C2), 12 ATLL with 13 T
FH
-PTCL (C3) and 24 ALK-negative ALCLs (C4) and the right branch 
contained two clusters of 16 NKTCL (C5) and 31 cytotoxic ALCLs (C6). 
Figure 2. Nodal PTCL with a double T
FH
/Th2 phenotype and a molecular Th2 signature. A) Diffuse 
proliferation of large pleomorphic cells; this case would be classified as T
FH
 PTCL according to the 
WHO2017, based on the expression of 2 T
FH
 markers, ie PD1 (b) and BCL6 (c), but disclosed strong 
nuclear staining for GATA3 in virtually all tumor cells (d) and, although less uniform, FOXP3 (e). Few 
tumor cells also expressed CD30 (f). RT-MLPA profile showed a Th2 signature and classified in the 
Th2 class by the SVM. 
 
Figure 3. Unsupervised hierarchical clustering of PTCLs including PTCL-NOS (n = 230). PTCL-NOS 
distributed among 6 defined clusters represented by colored bars under the heat map (from left to 
right): C1 (red), C2 (green), C3 HSTL (purple), C4 AITL/T
FH
-derived PTCLs (blue and light blue), C5 
NKTCL (yellow), and “cytotoxic ALCL” (orange and red). The 77 PTCL-NOS (grey in Pathology) are 
distributed among the subgroups 
Figure 4. A) Bioinformatic model for the analysis of RT-MLPA data. The SVM model attributes a 
predicted (rectangle) or provisional (oval) class for each PTCL sample. Post-tests based on ALK and 
CD30 were designed to distinguish between the subgroups in the heterogeneous “cytotoxic/ALCL-
like” category. B) PCA plot of the SVM classification for PTCL-NOS (n=77) showed 3 main molecular 
categories among: T
FH
/AITL (blue), Th2 (light blue), and cytotoxic/Th1 (green). The latter also 
comprised NKTCL-like (yellow) and ACL-like (orange) subgroups. Seven cases were unclassified (red). 
Figure 5. Kaplan Meier survival analysis  
A) Overall survival of the 108 patients corresponding of the main RT-MLPA subgroups (11 ALCL ALK+, 
10 cytotoxic ALCL ALK-, 24 non-cytotoxic ALCL ALK-, and 63 T
FH
/AITL) B) Overall survival of the main 
RT-MLPA subgroups according to the DUSP22 status within the non-cytotoxic ALCL ALK-negative 
category C) Overall survival of 43 PTCL,NOS according to the molecular status by RT-MLPA (19 
cytotoxic/TH1 and 24 TH2) D) Overall survival of 30 PTCL-NOS according to the 
immunohistochemistry data (19 GATA3, 11 TBX21). 





Supplemental Material 
Patients and tumor samples 
As shown in Figure S1, the cases were divided into two cohorts. The first cohort 
(classification cohort, n = 230) used to build and train a predictive classification model, was 
composed of 230 cases, including 30 AITLs, 33 TFH-PTCL, 21 ALK-positive anaplastic large cell 
lymphomas (ALCLs), 34 ALK-negative ALCLs, 16 extranodal NK/T-cell lymphomas, nasal-type 
(NKTCLs), 6 hepatosplenic T-cell lymphomas (HSTLs), and 13 adult T-cell 
leukemia/lymphomas (ATLLs), and 77 PTCL-NOS cases, according to the WHO 2017 
classification. The second cohort (diagnostic cohort) of 40 FFPE PTCL samples (6 ALK-positive 
ALCLs, 4 ALK-negative ALCLs, 13 AITLs, 9 NKTCLs, 6 ATLLs, and 2 PTCL-NOS) was used to 
validate the robustness of the assay and its reproducibility between three independent 
centers. 
Immunohistochemistry and EBV in situ hybridization 
Deparaffinized tissue sections were stained for a panel of T-cell (CD3, CD2, CD7, CD5, CD8, 
CD4), cytotoxic (TIA-1, granzyme B, perforin), TFH (PD1, CXCL13, BCL6, ICOS, CD10), follicular 
dendritic-cell (CD21, CD23), B-cell (CD20, CD79a, PAX5), and other (CD30, CD56, ALK) 
antigens. Immunostains for GATA3 (clone HG3-31, Santa Cruz Biotechnology, Santa Cruz, 
CA) and TBX21 (clone 4B10, BD Biosciences, San Jose, CA) were performed on a subset of 
cases. The scoring system was evaluated as follows: score 0: negative (below threshold of 
10% positive tumor cells), score 1: 10-50% positive tumor cells, score 2: >50% positive tumor 
cells as previously described (Dobay, Haematologica, 2017;102(4): e148-e151). The 
detection of EBV was performed by in situ hybridization using EBER probes and was scored 
as previously described (de Leval, Haemalogica 2015;100(9):e361-364): score 0: absence of 
large EBV-positive cells, score 1: up to 5 large EBV-positive cells per high power fields (hpf), 
score 2 : 5 to 50 per hpf and score 3 : > 50 per hpf , or sheets or aggregates of large EBV-
positive cells. 
 
FISH for DUSP22/IRF4 rearrangement 
Laboratory-developed fluorescence in situ hybridization FISH-probes using bacterial artificial 
chromosomes (BACs) were used to explore DUSP22/IRF4 rearrangements by interphase 
FISH in FFPE tissue sections of ALK-negative ALCL. Break-apart probes consisted of telomeric 
RP3-416J7 labelled with SpectrumOrangeTM and centromeric RP11-615C17 and CTD-
3139L20 labelled with SpectrumGreenTM (Institute of Pathology, Lausanne). 
 
Allele-specific PCR and targeted deep sequencing 
RHOA G17V and IDH2 R172K/T mutational status were also determined by allele-specific 
qPCR (AS-qPCR) or next generation sequencing (NGS) on a MiSeq instrument with a mean 
coverage depth of 1200X. (Dupuy et al. J Mol Diag) 
 
RNA extraction and microarray procedure 
Total RNA was extracted from frozen and FFPE tissue samples with Trizol reagent and the 
Maxwell 16 LEV RNA kit (Promega), respectively. High-throughput gene-expression data 
(HG-U133 plus 2.0 chips, Affymetrix, Santa Clara, CA) from 72 cases (23 AITL and 49 PTCL-
NOS) were previously reported (de Leval et al, Blood. 2007;109(11):4952–4963). 
 
RT-MLPA procedure 
All probes consisted of a gene-specific region complementary to the cDNA target linked to a 
tail. The 5’ and 3’ tails correspond to the primers U1 (TCCAACCCTTAGGGAACCC) and U2 
(GTGCCAGCAAGATCCAATCTAGA) used for the final PCR amplification step. Spacers were 
added between these tails and the gene-specific regions to allow the separation and 
identification of the PCR products based on size. The 3’ probes were phosphorylated at the 
5’ ends. For four genes, specific probes without the PCR tails were used as competitors to 
normalize the amplification signal. The competitors were added to the corresponding 
probes at a ratio of 1 (MLPA) to 4 (competitor) for GZB, CXCL13, TCRα1, and 1 (MLPA) to 3 
(competitor) for PRF. For the identification of RHOAG17V and IDH2R172K/T hotspot 
mutations, 5’ probes with the last nucleotide corresponding to the mutated nucleotide were 
designed. 
Bioinformatic analysis  
Starting from raw (.fsa) files generated by the genetic analyzer, the web interface provides a 
graphical representation of the gene expression profile and a table of normalized gene 
expression calculated as a function of the FAM fluorescence intensity normalized to the 
median intensity of the 20 genes of the signature. For each sample, this interface also 
returns a class prediction deduced from a support vector machine classifier (SVM), 
established using the e1071 R package with default settings. To minimize the risks of 
misclassification, this algorithm was coupled with a second nearest centroid classifier to 
minimize the risks of misclassification. For each class C, the coordinates of the centroid μc 
was calculated so that  
µ𝑐 =
1
𝑁
∑𝑆𝑖
𝑁
𝑖=1
 
where N represents the number of cases belonging to the class C defined by the SVM 
classifier in the training series and Si, a sample defined by the expression of the 20 RT-MLPA 
markers. For each sample Si, the distance d(Si, C) to the centroid μc of the class C is given by  
d(Si, C) =√∑ (𝑆𝑖 − µ
𝑁
𝑖=1 𝑐)² 
For each sample, the class prediction returned by the web interface consists of the results of 
the SVM algorithm completed by the arithmetic distance to the centroids of each class.  
A stratified cross validation was performed to assess the accuracy of our assay. A bootstrap 
resampling process was first used to build 100 independent training series, randomly 
selecting two-thirds of the samples within the six categories of the unsupervised hierarchical 
analysis. For each iteration, a SVM predictor was trained and tested against all remaining 
samples. A definitive SVM predictor was thus trained using the 184 cases classified by 
hierarchical analysis.  
Post-tests were then built to distinguish ALCL from cytotoxic/Th1 cases. A specific threshold 
was determined using ROC curves, based on the expression of the CD30 gene values by RT-
MLPA (CD30 threshold = 0.8). A second post-test was performed to distinguish ALK-positive 
from ALK-negative ALCLs, based on the expression of the ALK gene (threshold = 0.2).  
Another CD30 post-test was designed among the Th2 category to catch misclassified CD30-
positive Th2 cases (threshold = 1.4) due to overlapping FOXP3 and ICOS expression in both 
the CD30-positive and CD30-negative Th2 groups. 
An algorithm was finally performed to calculate the distance of the sample to the centroid 
of the predicted class and compare it to the other intraclass distances. The algorithm 
constructs a boxplot based on these intraclass distances and calculates the first and third 
quartile values, deducting the IQR (InterQuartile Range) value, which is equal to Q3-Q1.  
Finally, if the distance of the tested sample was higher than Q3 + 1.5 IQR, the sample was 
considered to be a mild outlier, which defined the NOS category. 
  
Tables 
Table S1- Sequences of the oligonucleotides used for the RT-MLPA assay. Genes are listed 
according to the probes size. Specific sequences are represented in pink (5’probe) and red (3’probe). 
The blue sequence corresponds to the common 5’ and 3’ tails. Nucleotides spacers are in green. 
 
  
Gene Oligo probe Sequence
CD8 CD8E5L 5'probe GTGCCAGCAAGATCCAATCTAGATCGTGCCGGTCTTCCTGCCAG
CD8E6R 3'probe CGAAGCCCACCACGACGCCTCCAACCCTTAGGGAACCC
IDH2R172K IDH2R172KL 5'probe GTGCCAGCAAGATCCAATCTAGACCAAGCCCATCACCATTGGCAA
IDH2R172T IDH2R172TL 5'probe GTGCCAGCAAGATCCAATCTAGACCAAGCCCATCACCATTGGCAC
IDH2R172KR 3'probe GCACGCCCATGGCGACCAGTTCCAACCCTTAGGGAACCC
EBER1 EBER1L 5'probe GTGCCAGCAAGATCCAATCTAGATACGTAGCCACCCGTCCCGGGTA
EBER1R 3'probe CAAGTCCCGGGTGGTGAGGATATCCAACCCTTAGGGAACCC
GATA3 GATA3E3L 5'probe GTGCCAGCAAGATCCAATCTAGACCTCATTAAGCCCAAGCGAAGGCTG
GATA3E4R 3'probe TCTGCAGCCAGGAGAGCAGGGACTCCAACCCTTAGGGAACCC
ALK ALKE23F 5'probe GTGCCAGCAAGATCCAATCTAGACCTCCGAGAGACCCGCCCTCGCCCG
ALKE24R 3'probe AGCCAGCCCTCCTCCCTGGCCATGCTCCAACCCTTAGGGAACCC
FOXP3 FOXP3E3L 5'probe GTGCCAGCAAGATCCAATCTAGATAGGACAGGCCACATTTCATGCACCAG
FOXP3E4R 3'probe CTCTCAACGGTGGATGCCCACGCTTCCAACCCTTAGGGAACCC
CD4 CD4E4L 5'probe GTGCCAGCAAGATCCAATCTAGAGAGGAGGTGCAATTGCTAGTGTTCGGAT
CD4E5R 3'probe TGACTGCCAACTCTGACACCCACCTTCCAACCCTTAGGGAACCC
CD30 CD30E3L 5'probe GTGCCAGCAAGATCCAATCTAGATTGTACAGCCTGCGTGACTTGTTCTCGAG
CD30E4R 3'probe ACGACCTCGTGGAGAAGACGCCGTACTCCAACCCTTAGGGAACCC
PFR PFRE2L 5'probe GTGCCAGCAAGATCCAATCTAGATAACACGGTGGAGTGCCGCTTCTACAG
PFRE3R 3'probe TTTCCATGTGGTACACACTCCCCCGTACTACTCCAACCCTTAGGGAACCC
BCL6 BCL6E3Lb 5'probe GTGCCAGCAAGATCCAATCTAGACATAAAACGGTCCTCATGGCCTGCAG
BCL6E4Rb 3'probe TGGCCTGTTCTATAGCATCTTTACAGACCAGTTGTCCAACCCTTAGGGAACCC
RHOA mut RHOmutL 5'probe GTGCCAGCAAGATCCAATCTAGAGGTGATTGTTGGTGATGGAGCCTGTGT
RHOA RHOR 3'probe AAAGACATGCTTGCTCATAGTCTTCAGCAAGGACCTCCAACCCTTAGGGAACCC
GZMB GRBE3L 5'probe GTGCCAGCAAGATCCAATCTAGATACTAACTTCTCCAACGACATCATGCTACTGCAG
GRBE4R 3'probe CTGGAGAGAAAGGCCAAGCGGACCAGTACTACTCCAACCCTTAGGGAACCC
TBET TBETE5L 5'probe GTGCCAGCAAGATCCAATCTAGATACTACCCAAAGGATTCCGGGAGAACTTTGAGTC
TBETE6R 3'probe CATGTACACATCTGTTGACACCAGCATCCCTACTTCCAACCCTTAGGGAACCC
CD56 CD56E11L 5'probe GTGCCAGCAAGATCCAATCTAGATACTACTACTCACCCCCTCTGCCAGCTATCTGGAG
CD56E12R 3'probe GTGACCCCAGACTCTGAGAATGATTTTGGTACTACTCCAACCCTTAGGGAACCC
CXCL13 CXCL13E2L 5'probe GTGCCAGCAAGATCCAATCTAGATACTACTGGTCAGCAGCCTCTCTCCAGTCCAAG
CXCL13E3R 3'probe GTGTTCTGGAGGTCTATTACACAAGCTTGAGGTGTTACTTCCAACCCTTAGGGAACCC
ICOS ICOSE2L 5'probe GTGCCAGCAAGATCCAATCTAGAAAAGTAACTCTTACAGGAGGATATTTGCATATTTATG
ICOSE3R 3'probe AATCACAACTTTGTTGCCAGCTGAAGTTCTGTACTACTTCCAACCCTTAGGGAACCC
TRAC TRACE3L 5'probe GTGCCAGCAAGATCCAATCTAGATACTACTACTACTACTACCTGCGGCTGTGGTCCAGCTGAG
TRACE4R 3'probe ATCTGCAAGATTGTAAGACAGCCTGTGCTCTACTACTATCCAACCCTTAGGGAACCC
CXCR5 CXCR5E1L 5'probe GTGCCAGCAAGATCCAATCTAGATACTACTACTACTACTGGACCTCGAGAACCTGGAGGACCTG
CXCR5E2R 3'probe TTCTGGGAACTGGACAGATTGGACAACTATAACGTACTACTCCAACCCTTAGGGAACCC
INFg INFgE3L 5'probe GTGCCAGCAAGATCCAATCTAGATACTAAACGAGATGACTTCGAAAAGCTGACTAATTATTCG
IFNgE4R 3'probe GTAACTGACTTGAATGTCCAACGCAAAGCATACTACTACTACTTCCAACCCTTAGGGAACCC
CCR4 CCR4E1L 5'probe GTGCCAGCAAGATCCAATCTAGATACTACTACTACTCCTCAGAGCCGCTTTCAGAAAAGCAAG
CCR4E2R 3'probe CTGCTTCTGGTTGGGCCCAGACCTTACTACTACTACTACTACTACTCCAACCCTTAGGGAACCC
Table S2. Comparison of RhoAG17V (n = 33) and IDH2R172K/T (n = 8) mutations detected by RT-
MLPA and next generation sequencing (NGS) or allele-specific-qPCR (AS-qPCR) analysis. 
Concordant results are represented in green, while discordant result in red. 
Id Pathology RhoAG17V status 
by RT-MLPA  
RhoA status by AS-qPCR 
/NGS (allele frequency)  
IDH2 R172K/T 
status by  RT-MLPA 
IDH2 status with AS-qPCR/ 
NGS (allele frequency) 
UPN001 AITL + +/NA  WT WT/NA 
UPN002 AITL + +/NA + +/NA 
UPN003 AITL + +/NA + +/NA 
UPN004 AITL + +/NA WT WT/NA 
UPN005 AITL + +/NA + +/NA 
UPN006 AITL + +/+ (6.12%) WT NA/NA 
UPN007 AITL + +/+ (19.27%) WT NA/NA 
UPN009 AITL + +/+ (12.93%) + +/+ (5.08%) 
UPN010 AITL + +/+ (8.53%) WT NA/NA 
UPN012 AITL + +/+ (23.3%) WT NA/NA 
UPN016 AITL + +/+ (22.38%) + +/+ (14.9%) 
UPN018 AITL + +/+ (9.13%) WT NA/NA 
UPN020 AITL + +/+ (12.24%) + +/+ (10.23%) 
UPN024 AITL + +/+ (18.2%) WT NA/NA 
UPN025 AITL + +/+ (7.44%) WT WT/+ (2.83%)  
UPN026 AITL + +/+ (17.52%) + +/NA 
UPN028 AITL + +/NA WT NA/NA 
UPN029 AITL + +/+ (18.31%) WT NA/NA 
UPN177 AITL + +/NA + +/NA 
UPN117 PTCL TFH + +/+ (38.93%) WT NA/NA 
UPN136 PTCL TFH + +/NA WT NA/NA 
UPN113 PTCL TFH + +/NA WT NA/NA 
UPN120 PTCL TFH + +/+ (23.54%) WT NA/NA 
UPN118 PTCL TFH + +/NA + +/+ (2.22%) 
UPN115 PTCL TFH + +/+ (23.15%) WT NA/NA 
UPN114 PTCL TFH + +/NA WT NA/NA 
UPN138 PTCL TFH + +/+ (21.87%) WT NA/NA 
UPN134 PTCL TFH + +/NA WT NA/NA 
UPN165 PTCL TFH + +/NA WT NA/NA 
UPN116 PTCLnos  + +/+ (50%) WT NA/NA 
UPN125 PTCLnos  + +/NA WT NA/NA 
UPN137 PTCLnos  + +/NA WT NA/NA 
UPN091 ATLL + +/NA WT NA/NA 
 
  
Table S3. Correlation scores of the RT-MLPA values (n = 20) of 40 FFPE samples between three 
independent centers (very strong correlation (VSC): rho > 0.9, strong correlation (SC) rho > 0.7)  
 
* There was no correlation for IDH2 R172m in the absence of IDH2 mutation detected in 
these 40 FFPE samples 
  
Table S4. Clinical parameters of ALK-negative ALCL and comparison of the non-cytotoxic ALCL ALK-
negative subgroup according to DUSP22 status 
 
  
p
median (IQ) % (n) median (IQ) % (n) median (IQ) % (n) median (IQ) % (n)
age median (range) 53.8 (40.8-67.2) 58 (52-70) 55 (43-72) 56.45 (53.1-70.3) 0.63
<= 60 years 63.6% (7/11) 54.2% (13/24) 62.5% (5/8) 62.5% (5/8) 1
gender male 53.8% (7/13) 79.2% (19/24) 87.5% (7/8) 75% (6/8) 1
IPI>=3 62.5% (5/8) 33.3% (7/21) 50% (4/8) 16.6% (1/6) 0.3
PIT>=2 85.7% (6/7) 42.8% (9/21) 50% (4/8) 16.6% (1/6) 0.3
extranodal site >=2 85.7% (6/7) 21.7% (5/23) 25% (2/8) 28.6% (2/7) 1
stage >=3 77.8% (7/9) 73.9% (17/23) 75% (6/8) 85.7% (6/7) 1
PS>=2 50% (4/8) 21% (4/19) 28.6% (2/7) 0 (0/5) 0.47
LDH>=1 38.5% (5/13) 50% (11/22) 50% (4/8) 60% (3/5) 1
B symptoms 50% (4/8) 35% (7/20) 57.1% (4/7) 20% (1/5) 0.33
Non-cytotoxic ALCL ALK-
negative n=24
DUSP22R (n=8) DUSP22NR (n=8)ALCL ALK- n=13
Figures 
Figure S1. Study design. 270 cases were divided into two cohorts. The classification cohort (n=230 
including 30 AITL, 33 PTCL-TFH, 55 ALCL, 13 ATLL, 6 HSTL, 16 NKTCL and 77 PTCL-NOS and consisting 
mostly of fresh-frozen (FF) samples) was used to train a SVM classifier. The diagnostic cohort (n=40 
including 13 AITL, 10 ALCL, 6 ATLL, 9 NKTCL and 2 PTCL-NOS) was used for the independent 
validation on FFPE samples and for the inter-laboratory reproducibility study. 
 
  
Figure S2. Representation of the RT-MLPA profiles of each PTCL molecular category 
A) AITL/TFH profile, showing the expression of CXCL13, CXCR5, ICOS, and BCL6, and in this case the 
presence of RHOA and IDH2 mutations. B) NKTCL signature, characterized by high EBER expression, 
and that of CD56 and cytotoxic markers. C and D) Cytotoxic ALCL profile, defined by the expression 
of CD30 and cytotoxic markers with (C) or without (D) ALK. E) Non-cytotoxic ALK-negative ALCL 
signature, characterized by the expression of CD30 and TH2 markers (GATA3 and CCR4). F) 
Cytotoxic/Th1 signature, defined by the expression of cytotoxic markers with inconsistent expression 
of Th1 markers. G) ATLL/TH2 signature, characterized by the expression of GATA3, CCR4, and ICOS, 
with inconsistent FOXP3 expression. H) HSTL profile, showing the expression of CD56, TBX21, 
GATA3, and BCL6. 
  
 
Figure S3. ALCL case reclassified from ALK-negative to ALK-positive based on RT-MLPA assay 
(UPN051) a) Histopathology of the misdiagnosed ALK- ALCL case, based on the negative 
immunohistochemistry with ALK1 (performed twice). Strong cytoplasmic staining with the D5F3 
clone was obtained, retrospectively. b) RT-MLPA profile of the case showing ALK expression (red 
arrow). c) Sequencing of the specific RT-PCR products confirmed an ATIC-ALK fusion transcript. No 
mutation in the region coding for the epitope of ALK1 was found (data not shown). 
 
  
Figure S4. Scatterplot representation of the correlation between RT-MLPA and Affymetrix gene 
expression values (n = 71 cases, 23 AITL, and 49 PTCL NOS). There were significant correlations 
(Spearman test, p < 0.05) for each gene, with rho > 0.9 for CXCL13 and CCR4, rho > 0.7 for PRF, 
GZMB, GATA3, ICOS, CXCR5, BCL6, TNFRSF8/CD30, CD8, and TBX21, and rho > 0.5 for CD4 and FOXP3 
(x = Affymetrix values log, y = RT-MLPA values). The correlation for ALK and CD56 was not 
determined because these genes were not evaluated in the Affymetrix series in the absence of ALCL, 
HSTL, and NKTCL. RHOAm, IDH2m, TCR, and EBER expression were not studied by the Affymetrix 
chip. 
 
  
Figure S5. Comparison of individual RT-MLPA gene expression values and immunohistochemical 
results in 224 PTCLs, including 20 ALK+ ALCLs, 34 ALK- ALCLs, 29 AITLs, 36 PTCL-TFH, 15 NKTCLs, 13 
ATLLs, 6 HSTLs, and 70 PTCL-NOS (6 cases with no IHC data were not considered). There was a 
significant correlation by Wilcoxon’s rank- sum test between the RT-MLPA expression level of each 
gene and negative (-) or positive (+) staining by immunohistochemistry (CD30, TBX21, PRF, GZMB, 
GATA3, ALK, CXCL13, CD56, ICOS, CD8, CD4, and BCL6) or in situ hybridization (EBER). 
 
  
 Figure S6. Examples of RT-MLPA profiles for paired FFPE and frozen samples. A) Superimposed 
profiles showed similar peaks for each 3 paired cases (NKTCL, AITL and non-cytotoxic ALK-negative 
ALCL). B) There was a strong correlation (rho>0.7) of RTMLPA normalized data between frozen (blue) 
and FFPE (orange) samples. 
  
Figure S7. Molecular prediction of PTCL-NOS (n = 77) by the SVM model and correlation with 
immunohistochemical data. The SVM classification is presented in the top line, the pathological 
diagnosis in the second line, and immunohistochemical markers in the map). The SVM proposed a 
molecular class for 92% (69/75) of PTCL-NOS: 17 with a TFH signature, 28 with a cytotoxic/Th1 
signature (5 ALK-negative ALCL, 19 cytotoxic/Th1, 5 NKTCL) and 24 with a Th2 signature.  Among 
the 29 cases with a cytotoxic molecular signature, 23 were characterized as cytotoxic by 
immunochemistry and 6 were undetermined. Among the 24 molecular Th2 PTCL-NOS, 
14/18 tested cases had a positive immunostaining for GATA3. Only four discrepancies (5%) 
were noted: 4 cases with a cytotoxic phenotype were classified in the TFH/ AITL group.  
 
 
 
